Potent antitumor effects of combined therapy with a telomerase-specific, replication-competent adenovirus (OBP-301) and il-2 in a mouse model of renal cell carcinoma

Peng Huang, H. Kaku, J. Chen, Y. Kashiwakura, T. Saika, Yasutomo Nasu, Y. Urata, Toshiyoshi Fujiwara, Masami Watanabe, H. Kumon

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

OBP-301 (a telomerase-specific, replication-competent adenovirus with hTERT promoter) was constructed in a previous study and it showed a strong anticancer effect by inducing cell lysis in human lung and prostate cancer cells. This study investigated the effectiveness of a combination therapy of OBP-301 and interleukin-2 (IL-2) in a mouse model of renal cell carcinoma (RCC). The cell-killing effect of OBP-301 was confirmed in vitro in the RENCA cancer cells. In in vivo experiment, luciferase-expressing RENCA cells were implanted in the left kidney and lung of BALB/c mice to prepare the RCC metastatic model. The animals were randomly divided into four treatment groups: PBS, IL-2 alone, OBP-301 alone and the combination. The analyses of orthotopic tumor weight, lung metastasis and luciferin-stained tumor images 14 days after each treatment showed significant tumor growth inhibition in the combination group in comparison with that in the OBP-301-or IL-2-treated groups. In addition, the percentage of regulatory T-cells (Tregs) in the combination group was significantly suppressed in comparison with that in the PBS and single-agent treatment groups. The outcomes of this study suggest that tumor-specific oncolytic immunovirotherapy may become an attractive strategy for the treatment of human RCC.

Original languageEnglish
Pages (from-to)484-491
Number of pages8
JournalCancer Gene Therapy
Volume17
Issue number7
DOIs
Publication statusPublished - Jul 2010

Fingerprint

Telomerase
Renal Cell Carcinoma
Adenoviridae
Interleukin-2
Neoplasms
Therapeutics
Lung
Regulatory T-Lymphocytes
Tumor Burden
Luciferases
Lung Neoplasms
Prostatic Neoplasms
Outcome Assessment (Health Care)
Neoplasm Metastasis
Kidney
Growth

Keywords

  • Adenovirus
  • HTERT
  • Interleukin-2
  • OBP-301
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Molecular Biology
  • Medicine(all)

Cite this

Potent antitumor effects of combined therapy with a telomerase-specific, replication-competent adenovirus (OBP-301) and il-2 in a mouse model of renal cell carcinoma. / Huang, Peng; Kaku, H.; Chen, J.; Kashiwakura, Y.; Saika, T.; Nasu, Yasutomo; Urata, Y.; Fujiwara, Toshiyoshi; Watanabe, Masami; Kumon, H.

In: Cancer Gene Therapy, Vol. 17, No. 7, 07.2010, p. 484-491.

Research output: Contribution to journalArticle

@article{935ce78b3ac946019627a2a723dc7e48,
title = "Potent antitumor effects of combined therapy with a telomerase-specific, replication-competent adenovirus (OBP-301) and il-2 in a mouse model of renal cell carcinoma",
abstract = "OBP-301 (a telomerase-specific, replication-competent adenovirus with hTERT promoter) was constructed in a previous study and it showed a strong anticancer effect by inducing cell lysis in human lung and prostate cancer cells. This study investigated the effectiveness of a combination therapy of OBP-301 and interleukin-2 (IL-2) in a mouse model of renal cell carcinoma (RCC). The cell-killing effect of OBP-301 was confirmed in vitro in the RENCA cancer cells. In in vivo experiment, luciferase-expressing RENCA cells were implanted in the left kidney and lung of BALB/c mice to prepare the RCC metastatic model. The animals were randomly divided into four treatment groups: PBS, IL-2 alone, OBP-301 alone and the combination. The analyses of orthotopic tumor weight, lung metastasis and luciferin-stained tumor images 14 days after each treatment showed significant tumor growth inhibition in the combination group in comparison with that in the OBP-301-or IL-2-treated groups. In addition, the percentage of regulatory T-cells (Tregs) in the combination group was significantly suppressed in comparison with that in the PBS and single-agent treatment groups. The outcomes of this study suggest that tumor-specific oncolytic immunovirotherapy may become an attractive strategy for the treatment of human RCC.",
keywords = "Adenovirus, HTERT, Interleukin-2, OBP-301, Renal cell carcinoma",
author = "Peng Huang and H. Kaku and J. Chen and Y. Kashiwakura and T. Saika and Yasutomo Nasu and Y. Urata and Toshiyoshi Fujiwara and Masami Watanabe and H. Kumon",
year = "2010",
month = "7",
doi = "10.1038/cgt.2010.5",
language = "English",
volume = "17",
pages = "484--491",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Potent antitumor effects of combined therapy with a telomerase-specific, replication-competent adenovirus (OBP-301) and il-2 in a mouse model of renal cell carcinoma

AU - Huang, Peng

AU - Kaku, H.

AU - Chen, J.

AU - Kashiwakura, Y.

AU - Saika, T.

AU - Nasu, Yasutomo

AU - Urata, Y.

AU - Fujiwara, Toshiyoshi

AU - Watanabe, Masami

AU - Kumon, H.

PY - 2010/7

Y1 - 2010/7

N2 - OBP-301 (a telomerase-specific, replication-competent adenovirus with hTERT promoter) was constructed in a previous study and it showed a strong anticancer effect by inducing cell lysis in human lung and prostate cancer cells. This study investigated the effectiveness of a combination therapy of OBP-301 and interleukin-2 (IL-2) in a mouse model of renal cell carcinoma (RCC). The cell-killing effect of OBP-301 was confirmed in vitro in the RENCA cancer cells. In in vivo experiment, luciferase-expressing RENCA cells were implanted in the left kidney and lung of BALB/c mice to prepare the RCC metastatic model. The animals were randomly divided into four treatment groups: PBS, IL-2 alone, OBP-301 alone and the combination. The analyses of orthotopic tumor weight, lung metastasis and luciferin-stained tumor images 14 days after each treatment showed significant tumor growth inhibition in the combination group in comparison with that in the OBP-301-or IL-2-treated groups. In addition, the percentage of regulatory T-cells (Tregs) in the combination group was significantly suppressed in comparison with that in the PBS and single-agent treatment groups. The outcomes of this study suggest that tumor-specific oncolytic immunovirotherapy may become an attractive strategy for the treatment of human RCC.

AB - OBP-301 (a telomerase-specific, replication-competent adenovirus with hTERT promoter) was constructed in a previous study and it showed a strong anticancer effect by inducing cell lysis in human lung and prostate cancer cells. This study investigated the effectiveness of a combination therapy of OBP-301 and interleukin-2 (IL-2) in a mouse model of renal cell carcinoma (RCC). The cell-killing effect of OBP-301 was confirmed in vitro in the RENCA cancer cells. In in vivo experiment, luciferase-expressing RENCA cells were implanted in the left kidney and lung of BALB/c mice to prepare the RCC metastatic model. The animals were randomly divided into four treatment groups: PBS, IL-2 alone, OBP-301 alone and the combination. The analyses of orthotopic tumor weight, lung metastasis and luciferin-stained tumor images 14 days after each treatment showed significant tumor growth inhibition in the combination group in comparison with that in the OBP-301-or IL-2-treated groups. In addition, the percentage of regulatory T-cells (Tregs) in the combination group was significantly suppressed in comparison with that in the PBS and single-agent treatment groups. The outcomes of this study suggest that tumor-specific oncolytic immunovirotherapy may become an attractive strategy for the treatment of human RCC.

KW - Adenovirus

KW - HTERT

KW - Interleukin-2

KW - OBP-301

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=77953716365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953716365&partnerID=8YFLogxK

U2 - 10.1038/cgt.2010.5

DO - 10.1038/cgt.2010.5

M3 - Article

C2 - 20168351

AN - SCOPUS:77953716365

VL - 17

SP - 484

EP - 491

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 7

ER -